Valirx Share Price (VAL)

[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  4.50 17.31% 30.50 3,323,413 16:45:47
Bid Price Offer Price High Price Low Price Open Price
30.50 31.00 30.75 25.25 26.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.54 -3.81 20
Last Trade Time Trade Type Trade Size Trade Price Currency
17:38:18 O 75,000 29.485 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Valirx (VAL) Latest News (2)

Valirx News

Date Time Source Headline
28/9/202116:40UKREGValiRx PLC Second Price Monitoring Extn
28/9/202116:36UKREGValiRx PLC Price Monitoring Extension
17/9/202116:40UKREGValiRx PLC Second Price Monitoring Extn
17/9/202116:36UKREGValiRx PLC Price Monitoring Extension
16/9/202118:19ALNCIN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment
16/9/202106:59UKREGValiRx PLC New Evaluation Agreement
08/9/202107:00UKREGValiRx PLC Holding(s) in Company
07/9/202115:05ALNCEARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips
07/9/202107:00UKREGValiRx PLC Half-year Report
25/8/202107:01UKREGValiRx PLC Appointment of Broker
More Valirx News
Valirx Investors    Valirx Takeover Rumours

Valirx (VAL) Discussions and Chat

Valirx Forums and Chat

Date Time Title Posts
28/9/202121:01VALIRX - A Significantly Undervalued Pharma3,356
23/9/202113:27RAINMAKER'S VALUE THREAD8,430
27/8/202111:08Valirx May 1st 2020 a New era begins1,980
12/1/202116:56Valirx: entering a new era!247
26/11/202015:47Valirx 24/07/2018 Post GM8,413

Add a New Thread

Valirx (VAL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:38:2529.4975,00022,113.75O
16:07:1130.5043,50013,267.50O
15:45:4730.503,3911,034.26UT
15:36:1630.00222,88266,864.60O
15:29:3830.645,0001,532.00O
View all Valirx trades in real-time

Valirx (VAL) Top Chat Posts

DateSubject
28/9/2021
09:20		Valirx Daily Update: Valirx Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 26p.
Valirx Plc has a 4 week average price of 19.15p and a 12 week average price of 17.85p.
The 1 year high share price is 67.50p while the 1 year low share price is currently 17.50p.
There are currently 64,882,490 shares in issue and the average daily traded volume is 915,067 shares. The market capitalisation of Valirx Plc is £19,789,159.45.
Read Full Thread
Reply
23/9/2021
11:00		rainmaker: French Connection Group PLC Statement Regarding Share Price Movement 23/09/2021 10:31am UK Regulatory (RNS & others) French Connection (LSE:FCCN) Intraday Stock Chart Thursday 23 September 2021 RNS Number : 7683M French Connection Group PLC 23 September 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT OF A POSSIBLE OFFER FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS. IT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. ACCORDINGLY, THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF RETAINED EU LAW (AS DEFINED IN THE EUROPEAN UNION (WITHDRAWAL) ACT 2018) ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN FOR THE PURPOSES OF MAR. French Connection Group PLC (the "Company") Statement Regarding Share Price Movement As announced on 2 March 2021, the Company is conducting a formal sale process. The Board of French Connection Group PLC notes the recent share price movement and confirms that it has received an approach from a consortium of bidders including the Company's second largest shareholder Apinder Singh Ghura, Amarjit Singh Grewal and KJR Brothers Limited (the "Consortium") as a potential offeror for French Connection Group Plc, which may or may not result in an offer for the Company. The indicated offer price is 30 pence per share in cash. Discussions with the Consortium remain ongoing. Accordingly, there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made (although any offer is likely to be in cash). Further announcements will be made as appropriate in due course. This announcement has been made without the consent of the Consortium. Enquiries: French Connection Group plc Neil Williams, Chief Operating Officer +44 (0) 20 7036 7206 WH Ireland (Sole Broker & Financial Adviser) Adam Pollock (Corporate Broking) Adrian Hadden / Ben Good (Corporate Finance) +44 (0) 20 7220 1666 Paternoster Communications Tom Buchanan +44 (0) 20 3012 0241 Further information WH Ireland Limited, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for the Company and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement. This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of any offer to buy, sell, subscribe for any securities or the solicitation of any vote in any jurisdiction. The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction. Disclosure requirements of the Takeover Code Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure. Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure. Website publication In accordance with Rule 26.1 of the Code, a copy of this announcement will be published on the Company's website at www.frenchconnection.com promptly and by no later than 12 noon (London time) on the business day following this announcement. The content of this website is not incorporated in, and does not form part of, this announcement. Rule 2.9 disclosure In accordance with Rule 2.9 of the Code, the Company confirms that, as at the date of this announcement, its issued and fully paid share capital consists of 96,612,934 ordinary shares with a nominal value of 1 pence each. The International Securities Identification Number (ISIN) for the ordinary shares is GB0033764746. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END SPMFZGZLLFGGMZG (END) Dow Jones Newswires
Read Full Thread
Follow
Reply
21/9/2021
13:30		rainmaker: One of the leading AIM stockbrokers, Cenkos Securities(CNKS) with a 37% increase in turnover, a 44 lift in profits and a 25% rise in the dividend in their recent interim results to 30 June 021, are doing very well but trading at a substantial discount to their 10 year average earnings. Furthermore their much improved operating performance has accelerated with a strong start to the second half in July gathering pace into August and September with some 10 deals done already v 16 in the whole of the first half of the year.This is all the more remarkable when you consider that these months are traditionally quieter, summer holiday months. In the words of Ben Graham " In the short term the market is a voting machine but in the long run it is a weighing machine" and eventually the share price, currently lagging at 84p/87p, will begin to reflect much improved trading and growth, in a higher share price. AIMHO, DYOR as I have done mine. regards Edit 13.37, 21/9/2021 correction.
Read Full Thread
Follow
Reply
16/9/2021
07:18		uknighted: RNS ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered an Evaluation Agreement with a leading London university to investigate a novel technology designed to treat breast cancer. Under the agreement, the Company will carry out a defined series of preclinical tests on the drug candidate molecule over the next nine months to validate the technology and determine suitability for commercialisation. This preclinical evaluation, the cost of which will be borne by ValiRx up to £75,000, will investigate the action of the molecule against Triple Negative Breast Cancer and other indications. At the conclusion of the evaluation period the Company has an option to license the technology on pre-agreed terms.
Read Full Thread
Follow
Reply
07/9/2021
11:03		rainmaker: Thanks OnJohn-I'm greatly humbled and sincere thanks also Simmsc-you're decently diversified which is always good to see-imho that's far and away the number 1 mistake Private Investors make-diversification has to be the first rule of stockmarket investment, period. I think Volex's most telling financial, poignant ratio is the price/sales ratio and as I commented some posts ago, IMHO there is a huge discrepancy in that rating which even after large rises in the share price recently is only 2.21 times yet the sector is on something like a 6.41 average rating which equates to some a £13.50 Volex share price IF you believe it deserves an average multiple of sales??!!. As I said, something has to give with the p/s ratio and I believed then as I believe now that it will resolved by a sharply higher share price. Overwhelmingly you only get out of something what you put in so IMHO its incredibly important to research prospective purchases, their markets, their products, their competitors thoroughly before you start keep pressing that confirm button.As Warren Buffett says"If you bring nothing to the Party, how can you expect to take anything home?" I want to tag a couple more Companies as opportunities- Cenkos Securities(CNKS),currently 78p bid, 81p offered, market cap £45.1mln, net cash of £32.7mln(up from £18.3mln in previous year) 3.5p/4.4% Historic Dividend yield. P/E 21.5 times One of the leading AIM stockbrokers. IMHO considerable uncertainty created by shock EU referendum leave result in June 2016 and Covid-19 pandemic have conspired to create a terrific buying opportunity. Company made first ever loss in 2019 a paltry £200k since its inception in 2004 but under normal trading conditions the Company is a very profitable business, making £30mln and £23mln annual pre tax profits in 2015 and 2016 before Brexit induced paralysis set in and floatations, its main profits driver, reduced to a trickle. However trade deal with EU struck at the end of last year and IPOs for the first quarter this year were back with a bang and the best since 2007. Current trading believed to be ahead of last year. IMHO you have to put your faith and trust in this Company’s excellent long term track as they have raised some £21bln for Clients and returned 178p+ to shareholders over the years. Looking for its share price to move to 250p/300p in the next year to 18 months as its trading returns to more typical levels.Strip out the Company's net cash and you're paying just £12mln for a company capable of making £30mln, that's some deal! Orchard Funding(ORCH), currently 57p bid 61p offered. Will update later when I have time. AIMHO, DYOR as I have done mine regards
Read Full Thread
Follow
Reply
25/8/2021
08:07		base7: Clearly should our share price increase by 50p every ones a winner but I agree with Nico in that why should Cenkos,given that scenario,make £2mill profit for no risk.It would be interesting to know what was so compelling about the Cenkos proposition & what they may have "promised" our Board which share price Angel or any other broker could not have achieved.A structured warrant deal rewarding them for success but not prospectively so generously.I do not recollect another investment which I have made,including many micro companies, in which brokers could benefit so substantially ( prospectively) I appreciate that the downside for Cenkos is that Val fail & they dont get their reward -,but they will, I am sure, be receiving fees too.
Read Full Thread
Follow
Reply
15/7/2021
00:42		rainmaker: Hi Boystown, sorry,apologies I see what you mean, I've just copied the message from the Volex thread :-( I originally bought Volex(VLX)some 5 years ago at around a tenth of the current share price, I even put it in the list of shares above but will not be selling now and intend to hold for several more years during which time I expect the share price to perform spectacularly well from strong growth in earnings and a dramatic and very substantial rerating as thematic investors become involved to exploit a widely anticipated and eagerly awaited boom in Electric Vehicles. Volex(VLX) design and manufacture the charger cables for Electric Vehicles(EV)-Tesla are major clients- so are at the very cutting edge of the biggest revolution ever to happen to the multi billion pound automobile industry and we're only just at the onset. In 2020, just 3% of new cars were EV but UBS forecast this to rise to 20% in 2025, 50% in 2030 and virtually 100% in 2040. Meanwhile Volex's sales to EV manufacturers, despite a subdued 1st quarter due to the Covid Pandemic, nearly tripled from US $18.1mln to US $53.1mln in the year to 6 April 2021. At the moment EV are a relatively small part of the overall business, about 10% and clearly this will enjoy terrific growth over the coming years from a very low base. They also have other good businesses, in manufacturing critical components for medical equipment,higher margin complicated electrical engineering assembly which are performing well but none have the spectacular growth prospects in supplying a rapidly expanding Electic Vehicle market. Incredibly given the terrific performance of Volex's EV division and new EV sales beginning to accelerate hard and for a Company with net margins that are strong at 9.7% and expanding, the Company has a relatively modest rating, trading around 18 times earnings and just 1.8 times sales. I believe that a Company with its growth prospects with these value metrics should be trading at between 4 to 6 times sales even before we enjoy any real growth.I firmly believe that The Market cannot coup or absorb the sheer enormity of the growth in the EV market or the growth in earnings from Volex and are way behind the curve on this one.For example and for the purpose of illustration, a 193% growth rate compounded means US $3.5bln(sic) in sales in the year to April 2025. I don't seriously expect their EV sales to reach that level so quickly so its more of a practical demonstration of the magic of compounding sales growth at very high rates.Moreover not only do I expect VLX's earnings to grow very strongly in the comings years but I confidentally expect their rating to balloon. I've seen this happen in similar situations in industries that are about to undergo huge technological change and there are tremendous growth opportunities for well positioned Companies able to benefit for this enormous change eg one Company that went from just 5 times historic earnings to 750 times in just two years.IMHO you get very, very few such opportunities and you need to take full advantage of each one. AIMHO,DYOR as I have done mine regards
Read Full Thread
Follow
Reply
09/7/2021
23:20		rainmaker: Ben Graham's allegory, "Mr Market" is a fictional manic depressive fellow shareholder in a business who has wild irrational mood swings and the daily prices he offers to sell you his holding or buy out yours often reflect his range of emotions from unbridled euphoria to extreme pessimism. hxxps://www.gurufocus.com/news/168996/what-ben-grahams-mr-market-metaphor-really-means https://en.wikipedia.org/wiki/Mr._Market hxxp://www.buffettsecrets.com/mr-market.htm 1)Always remember "The Market" is there to serve you and not you serve "The Market".He is there for your convenience and just because he is sometimes offering sharply differing prices does not mean that you should be induced to dealing with him. 2)Never take investment advice or follow guidance from "Mr Market", buying a share after a steep increase in price or selling after a large decline, as that will surely lead to financial ruin. 3)"Mr Market" will take no offence if you refuse to accept his prices and will be back again tomorrow to offer you more prices. You have no obligation to deal with him and if you do not like his prices and they do not suit you then you do nothing. 4)Remember that sometimes the prices "Mr Market" quotes daily will seem plausible given the Company's current trading performance and prospects yet at other times they have absolutely no bearing to known facts and will make no sense then you free to take full advantage. 5) Be patient and wait for to catch "Mr Market" to be in a very good mood and to accept his very high price for your holding 6) Independant of share price moves,think rationally about a conservative valuation of your holding. regards
Read Full Thread
Follow
Reply
06/7/2021
17:09		rainmaker: For anyone holding or has an interest, fashion retailer, French Connection(FCCN), 18.70p/18.85p currently subject to bid interest from three separate parties are due a trading statement this month. Last years was on 24/7/2020. You would think that current trading would be good, April's retail sales were the best since August last year. A constant stream of selling from impatient holders has kept the share price under pressure. IMHO a bid was never going to come quickly, the CEO, founder and 41% shareholder apparently rejected a 42p a share last January and he obviously, and very reasonably wants a lot more. I calculate French Connection's intrinsic value to be circa 120p a share(its not that difficult to work out) and of course no one will pay anything like that in the current economic climate and with FC's current trading performance unless someone makes a move and they go into play. FC have a valuable brand and IMHO is worth a great deal more than the current share price-just ask DFS. AIMHO, DYOR as I have done mine. regards
Read Full Thread
Follow
Reply
06/7/2021
14:05		rainmaker: Re Cenkos(CNKS) Rainmaker2 Jul '21 - 14:18 - 3861 of 3875 Edit I'm almost certainly in a minority, in thinking that Cenkos Securities at current prices, is a great opportunity but that doesn't bother me as you can't obtain market beating returns by agreeing with the consensus. You just have to think and act independently, think about what makes sense and try to base you opinions on facts. Rainmaker2 Jul '21 - 15:08 - 3863 of 3875 Edit Thanks Brucie, IMHO you shouldn't be in a hurry to sell, wouldn't you rather sell at 240p or 360p than 120p? Just leave it as you make the really serious money in the Stockmarket by sleeping and doing nothing. Warren Buffett never became the worlds richest man through day trading! regards Thanks Ken, I believe as a long standing Stockmarket Value Investor, its very important to think logically and rationally with sound reasoning,think long term and try to base your decisions on hard facts and to ignore short term news or lack of news eg IPOs which I consider to be "noise" and an unwelcome distraction but this noise sometimes creates great opportunities. I am reminded of the Warren Buffett quote "To a Man with a Hammer everything looks like a Nail". I can't blame anyone checking new IPOs on a daily basis because you have access to that information and you're a shareholder and you're naturally interested in this Company's progress but I believe its dangerous to do so since you are studying the short term in detail and isolation when its the long term trend that matters. With an outstanding trading history, I believe that you have to put your faith and trust in the Company's long term track record and give them the benefit of the doubt. I think they have earned that right. Try to focus on a £1 coin that you have bought for a 50 pence piece and be very tenacious and determined to sell at its true worth. regards Rainmaker2 Jul '21 - 16:38 - 3868 of 3875 Edit I think Cenkos previous problems makes sense, if you understand that IPOs dried up when we had the shock EU referendum vote to leave in June 2016(freedom day, that was a great day!) it created enormous doubt and uncertainty then there was a petition with 3mln+ signatorees for another vote to reverse the decision then you had PM Teresa May going to the Country to increase her majority and flopping then trying and failing to get acts through parliament. Its very understandable that Companies would not want to come to the market with this incredible uncertainty and no trade deal, are we staying or leaving the EU and if so when and on what terms and conditions? I think its very important that Investors understand Companies and their markets and the various factors impacting upon their trading performance. regards Rainmaker2 Jul '21 - 18:46 - 3869 of 3875 Edit Re technical analysis, IMHO fundamentals are the absolute king, no question. I believe Cenkos corporate finance department that deals with IPOs, the bulk of the business and the main profit driver at approx 75% of turnover, has a very bright future and as I expected, we have struck a trade deal with the EU(with a large trade surplus with the UK, they couldn't afford not to)and Covid 19 virus is now under control so I'm confident about Cenkos prospects. I know technical analysis inside out, as I have been using it for a number of years and I will use it when appropriate and relevant as I find it useful for timing trades and spotting confirmation of opportunities that the Market will miss. For example I have numerous holdings in Hong Kong stock exchange listed business where for several reasons, I expected a substantial rise in the share price. The share price of this Company was trading at historically very low levels, bumping along the bottom with little interest and small daily volume then one day, it broke into new low ground but then rallied to close above the previous day's high-what technicians refer to as a key or acute reversal, a powerful technical indicator that a sudden trend reversal is imminent and it did it on, and was validated by, so called "explosive" volume, 4 times the three month daily average and I immediately starting buying and within a few days or so, the share price had doubled and a month to six weeks it had gone up three fold........ regards Rainmaker2 Jul '21 - 19:59 - 3871 of 3875 Edit Hi QuePassa, if you're a holder IMHO you just have to stick with it. "buy low, sell high" as the old Wall Street adage goes, simple in theory but more difficult in practice.Presumably you've done the first bit now you just have to wait and be patient for the company's performance to return to more typical levels of trading activity. Under normal market conditions Cenkos is an excellent Company but they've had external problems that are not of their making but now they've overcome them and IMHO their outlook is bright. IMHO you just need to give them time and not be frightened,bored,distracted, frustrated or misled into liquidating your holding because IMHO they're worth a great deal more than their current share price and all you have to do is wait. If you're not familiar with Ben Graham's entertaining allegory(a story with a bigger meaning) "Mr Market" I would definitely have a read, as it will be a revelation and change your whole outlook and attitude towards the Stockmarket. Let me try to find a copy and post it here. Good Luck regards
Read Full Thread
Follow
Reply
10/6/2021
14:01		rainmaker: Here's what I wrote on another value thread-code VALUE on 20 May 2021 but note that both Company share prices have risen so you'll need to adjust the figures accordingly- "A Value Investing forum, I can't resist, I have to make a quick "pit stop".Heres a couple of IMHO impressive "net nets" that I recently bought and haven't seen mentioned on this thread- Orchard Funding(ORCH) Market Cap £11.2mln Number of shares 21.4mln Share price 52.5p Spread 50p/55p p/e 8.13 Dividend yield 5.71% Trading at 6.75 times, 7 year average earnings. Net Working Capital-£15.43mln or 72.11p a share Bargain Ratio 1.37 Vector Capital(VCAP) Market Cap £20.4mln Number of shares 42.0mln Share price 48.5p Spread 46p/51p p/e 8.69 Dividend yield 2.94% but forecast to increase to 5.36% Trading at 12.37 times 3 year average earnings. Net Working Capital-£21.297 or 50.7p a share Bargain Ratio 1.04 The reason I've bought both shares is that they are not only both very cheap, Ben Graham "bargains" but also they are both good businesses and consistently profitable,with great margins, making returns on capital employed in double digits. There're also long established and proven businesses. I believe that Vector Capital was founded in 1978 and Orchard Funding has been around some 23 years. Both pay dividends so effectively you are being paid to wait for an increase in the share price. Both are involved in the funding business, effectively they borrow money to lend at a higher rate. Its a simple and easy to understand business model.Orchard provides customised financial fee funding solutions to accounting firms, professionals and small businesses. Through their subsidiary Bexhill, there are also involved in insurance premium funding so rather than a Customer having to pay the whole annual premium in one go, they arrange instalments say quarterly or even monthly. I read that they have never had a customer default on a payment. I'm holding both for at least a couple of years and expect to do well. AIMHO, DYOR I'll try to update more on Vector Capital later.
Read Full Thread
Follow
Reply
Valirx share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VAL
Valirx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210928 23:51:47